Robert Kloppenburg
Direttore/Membro del Consiglio presso Institute for Healthcare Communication, Inc.
Profilo
Robert Kloppenburg is currently the Director at the Institute for Healthcare Communication, Inc. He previously worked as the Senior Director of Corporate Communications at Millennium Pharmaceuticals, Inc. from 2001 to 2003.
He also held positions as the VP of Investor Relations & Corporate Communications at Synta Pharmaceuticals Corp., the SVP & Head of Boston Life Sciences Practice at Fleishman-Hillard, Inc., and the VP of Corporate Communications & Public Affairs at AVEO Pharmaceuticals, Inc. Kloppenburg received his undergraduate degree from Carleton University.
Posizioni attive di Robert Kloppenburg
| Società | Posizione | Inizio |
|---|---|---|
| Institute for Healthcare Communication, Inc. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Robert Kloppenburg
| Società | Posizione | Fine |
|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Public Communications Contact | 01/01/2003 |
| AVEO PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | - |
Fleishman-Hillard, Inc.
 Fleishman-Hillard, Inc. Miscellaneous Commercial ServicesCommercial Services Fleishman Hillard, Inc. is a strategic communications company. It provides public relations, public affairs and marketing communications services. The company was founded in 1946 and is headquartered in St. Louis, MO. | Corporate Officer/Principal | - |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Contatto Relazioni con gli Investitori | - |
Formazione di Robert Kloppenburg
| Carleton University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Fleishman-Hillard, Inc.
Fleishman-Hillard, Inc. Miscellaneous Commercial ServicesCommercial Services Fleishman Hillard, Inc. is a strategic communications company. It provides public relations, public affairs and marketing communications services. The company was founded in 1946 and is headquartered in St. Louis, MO. | Commercial Services |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
| Institute for Healthcare Communication, Inc. | |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Robert Kloppenburg
